TY - JOUR T1 - Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) JF - medRxiv DO - 10.1101/2020.07.04.20142752 SP - 2020.07.04.20142752 AU - Conor Gruber AU - Roosheel Patel AU - Rebecca Trachman AU - Lauren Lepow AU - Fatima Amanat AU - Florian Krammer AU - Karen M. Wilson AU - Kenan Onel AU - Daniel Geanon AU - Kevin Tuballes AU - Manishkumar Patel AU - Konstantinos Mouskas AU - Nicole Simons AU - Vanessa Barcessat AU - Diane Del Valle AU - Samantha Udondem AU - Gurpawan Kang AU - Sandeep Gangadharan AU - George Ofori-Amanfo AU - Adeeb Rahman AU - Seunghee Kim-Schulze AU - Alexander Charney AU - Sacha Gnjatic AU - Bruce D. Gelb AU - Miriam Merad AU - Dusan Bogunovic Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/06/2020.07.04.20142752.abstract N2 - Initially, the global outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spared children from severe disease. However, after the initial wave of infections, clusters of a novel hyperinflammatory disease have been reported in regions with ongoing SARS-CoV-2 epidemics. While the characteristic clinical features are becoming clear, the pathophysiology remains unknown. Herein, we report on the immune profiles of eight Multisystem Inflammatory Syndrome in Children (MIS-C) cases. We document that all MIS-C patients had evidence of prior SARS-CoV-2 exposure, mounting an antibody response with normal isotype-switching and neutralization capability. We further profiled the secreted immune response by high-dimensional cytokine assays, which identified elevated signatures of inflammation (IL-18 and IL-6), lymphocytic and myeloid chemotaxis and activation (CCL3, CCL4, and CDCP1) and mucosal immune dysregulation (IL-17A, CCL20, CCL28). Mass cytometry immunophenotyping of peripheral blood revealed reductions of mDC1 and non-classical monocytes, as well as both NK- and T-lymphocytes, suggesting extravasation to affected tissues. Markers of activated myeloid function were also evident, including upregulation of ICAM1 and FcγR1 in neutrophil and non-classical monocytes, well-documented markers in autoinflammation and autoimmunity that indicate enhanced antigen presentation and Fc-mediated responses. Finally, to assess the role for autoimmunity secondary to infection, we profiled the auto-antigen reactivity of MIS-C plasma, which revealed both known disease-associated autoantibodies (anti-La) and novel candidates that recognize endothelial, gastrointestinal and immune-cell antigens. All patients were treated with anti-IL6R antibody or IVIG, which led to rapid disease resolution tracking with normalization of inflammatory markers.One Sentence Summary This study maps the cellular and serological immune dysfunction underlying a novel pediatric inflammatory syndrome associated with SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by National Institute of Allergy and Infectious Diseases Grants R01AI127372, R21 AI134366 and R21AI129827, and funding from the March of Dimes, awarded to DB. CG was supported by T32 training grant 5T32HD075735-07. S.G., D.M.D.V.. S.K.-S., A.R. and M.M. were supported by NCI U24 grant CA224319. S.G. is additionally supported by grants U01 DK124165, P01 CA190174, PCF Challenge Award and DOD W81XWH-18-1-0528. M.M. was supported by the fast-grant fund. The Human Immune Monitoring Center and the Institute for Healthcare Delivery Science received support from Cancer Center P30 grant CA196521.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mount Sinai Institutional Review Board (IF# 2641396; Characterizing the Immune Response to COVID-19 Infection).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request to the authors. ER -